TOCILIZUMAB
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL syringes
TOCILIZUMAB (11741Y)
11741Y
Manner of administration:Injection
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break
in biological medicine of less than 24 months)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological
medicine of more than 24 months)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Balance of supply - Initial treatment - Initial 1 (new patient) or Initial 2 (change
or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement
of treatment after a break in biological medicine of more than 24 months)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 4 | # of repeats: 3 | DPMQ: $801.70 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Actemra Subcutaneous Injection | |||||